Ultragenyx sells second rare pediatric PRV in a week for $203m
Ultragenyx sold a rare pediatric PRV for $203M, its second such sale in a week. The voucher was earned after FDA approval of FAYUVI for MPS IIIA. The buyer is undisclosed. The deal follows a $210M sale of another PRV, totaling $413M. The company plans to use the funds for R&D and profitability.
How this was made
The 30-second read
Why it matters
The transaction provides $413 M in total non‑dilutive capital, likely improving liquidity and enabling further R&D investment.
Market read
A sizable, first‑report capital raise for a mid‑cap biotech, with direct price implications.
What to watch
Future pipeline risk if the company becomes dependent on voucher proceeds rather than product sales.
Background
Ultragenyx (RARE) has previously sold a PRV for $210 M; the new $203 M sale doubles its recent voucher revenue, supporting its profitability goals.
Ticker impact
Ultragenyx disclosed a $203 million sale of a rare‑pediatric Priority Review Voucher, its second such sale within a week, providing significant non‑dilutive capital.
likely upward pressure as investors price in the large non‑dilutive funding.
A $203 M voucher sale is a material capital event for a mid‑cap biotech; markets typically reward such cash infusions.
Market effects
demonstrates the value of PRV assets, potentially encouraging other rare‑disease biotech firms to monetize similar vouchers.
U.S. biotech financing environment sees increased non‑dilutive capital options.
Highlights the growing importance of FDA PRV program worldwide.
Counterpoint
The cash may mask underlying cash‑burn concerns; investors could view reliance on voucher sales as a red flag.
Key entities
- companyUltragenyx Pharmaceutical
Biotech developer of rare‑disease therapies, ticker RARE.
